HIMS Director Christopher Payne Receives RSU Award

What Happened

• Christopher D. Payne, a director of Hims & Hers Health, Inc. (HIMS), was granted two awards of Restricted Stock Units (RSUs) on 2026-08-12: 8,223 RSUs and 545 RSUs (total 8,768 RSUs). These are derivative awards (acquisition code A) and were reported on Form 4 filed 2026-08-14.
• The 545-RSU portion was issued in lieu of a $16,598 director retainer; the filing cites a grant price of $30.40 to calculate that value. RSUs are granted at $0.00 in the table because they represent a contingent right to receive shares, not a cash purchase.

Key Details

• Transaction date: 2026-08-12; Form 4 filed: 2026-08-14.
• Award details: 8,223 RSUs (F1/F2) and 545 RSUs issued in lieu of cash retainer (F3).
• Price shown: $0.00 (typical for RSU grants — these are derivative awards). The filing uses $30.40 to value the 545-RSU portion ($16,598).
• Vesting: RSUs convert 1:1 to Class A common shares (F1). The 8,223 RSUs vest per the schedule described in F2 (vesting on the first company quarterly vesting date after the earlier of the next annual meeting or the first anniversary), while the 545 RSUs will vest in full on the company’s next quarterly vesting date (F3).
• Shares owned after transaction: not disclosed in this Form 4.
• Timeliness: Reported two days after the grants (transaction 8/12, filed 8/14), consistent with standard Form 4 reporting windows.

Context

• These grants are compensation to a director under the company’s director compensation policy (not an open-market purchase or sale). Such awards increase potential future ownership if and when they vest and convert to shares, but they are routine compensation and do not necessarily signal the director’s trading sentiment.
• RSUs are derivative awards (not immediate shares). Vesting conditions must be met (continuous service and specified vesting dates) before shares are issued.